JP2024543024A5 - - Google Patents
Info
- Publication number
- JP2024543024A5 JP2024543024A5 JP2024525946A JP2024525946A JP2024543024A5 JP 2024543024 A5 JP2024543024 A5 JP 2024543024A5 JP 2024525946 A JP2024525946 A JP 2024525946A JP 2024525946 A JP2024525946 A JP 2024525946A JP 2024543024 A5 JP2024543024 A5 JP 2024543024A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- mica
- cell
- antigen
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163263758P | 2021-11-08 | 2021-11-08 | |
| US63/263,758 | 2021-11-08 | ||
| US202163265192P | 2021-12-09 | 2021-12-09 | |
| US63/265,192 | 2021-12-09 | ||
| PCT/US2022/079419 WO2023081901A1 (en) | 2021-11-08 | 2022-11-07 | Engineered effector cells and methods of enhancing ubiquitous targeting of solid tumors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024543024A JP2024543024A (ja) | 2024-11-19 |
| JP2024543024A5 true JP2024543024A5 (https=) | 2025-11-17 |
Family
ID=86242040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024525946A Pending JP2024543024A (ja) | 2021-11-08 | 2022-11-07 | 操作されたエフェクター細胞及び固形腫瘍の広範な標的化を増強する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250018034A1 (https=) |
| EP (1) | EP4429681A4 (https=) |
| JP (1) | JP2024543024A (https=) |
| KR (1) | KR20240102994A (https=) |
| AU (1) | AU2022382407A1 (https=) |
| CA (1) | CA3236261A1 (https=) |
| WO (1) | WO2023081901A1 (https=) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117327184B (zh) * | 2023-12-01 | 2024-03-05 | 赛奥斯博生物科技(北京)有限公司 | 一种靶向msln的嵌合抗原受体及其应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL316257A (en) * | 2017-12-22 | 2024-12-01 | Fate Therapeutics Inc | Enhanced immune effector cells and use thereof |
| CN114258429A (zh) * | 2019-07-17 | 2022-03-29 | 菲特治疗公司 | 免疫效应细胞工程化和其用途 |
| MX2022003414A (es) * | 2019-09-25 | 2022-04-18 | Fate Therapeutics Inc | Celulas efectoras con multiples objetivos y uso de las mismas. |
| EP4045539A4 (en) * | 2019-10-17 | 2024-03-13 | Fate Therapeutics, Inc. | Enhanced chimeric antigen receptor for immune effector cell engineering and use thereof |
| US20230016034A1 (en) * | 2019-12-06 | 2023-01-19 | Fate Therapeutics, Inc. | ENHANCEMENT OF iPSC-DERIVED EFFECTOR IMMUNE CELL USING SMALL COMPOUNDS |
-
2022
- 2022-11-07 KR KR1020247018469A patent/KR20240102994A/ko active Pending
- 2022-11-07 EP EP22891146.7A patent/EP4429681A4/en active Pending
- 2022-11-07 AU AU2022382407A patent/AU2022382407A1/en active Pending
- 2022-11-07 CA CA3236261A patent/CA3236261A1/en active Pending
- 2022-11-07 JP JP2024525946A patent/JP2024543024A/ja active Pending
- 2022-11-07 WO PCT/US2022/079419 patent/WO2023081901A1/en not_active Ceased
- 2022-11-07 US US18/706,961 patent/US20250018034A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Exploring treatment options in cancer: tumor treatment strategies | |
| Jogalekar et al. | CAR T-Cell-Based gene therapy for cancers: new perspectives, challenges, and clinical developments | |
| Alnefaie et al. | Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions | |
| Tang et al. | Immunotherapy in hematologic malignancies: achievements, challenges and future prospects | |
| JP2022541441A5 (https=) | ||
| JP2022548943A5 (https=) | ||
| Barzaman et al. | Breast cancer immunotherapy: Current and novel approaches | |
| Thakur et al. | Cancer therapy with bispecific antibodies: Clinical experience | |
| JP2022510207A5 (https=) | ||
| Li et al. | Increasing the safety and efficacy of chimeric antigen receptor T cell therapy | |
| JP6678215B2 (ja) | がんにおけるｃｄ１３８の標的化 | |
| JP2023505206A5 (https=) | ||
| JP2021505131A5 (https=) | ||
| JP2022550899A5 (https=) | ||
| Maher | Immunotherapy of malignant disease using chimeric antigen receptor engrafted T cells | |
| Berry et al. | Adoptive immunotherapy for cancer: the next generation of gene‐engineered immune cells | |
| JP2023548829A5 (https=) | ||
| JP2023530704A5 (https=) | ||
| JP2023548467A5 (https=) | ||
| JP2023549098A5 (https=) | ||
| JP7319250B2 (ja) | Ｓｔｒｅｐ－タグ特異的結合タンパク質およびその使用 | |
| Caligiuri et al. | Immunotherapeutic approaches for hematologic malignancies | |
| JP2023545992A5 (https=) | ||
| Wang et al. | Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting | |
| Bonifant et al. | Advances in immunotherapy for pediatric acute myeloid leukemia |